

PROJECT BIOSHIELD



About

This July 21, 2024, marks the 20th anniversary of the Project BioShield Act of 2004 (P.L. 109-276); legislation enacted in response to the anthrax attacks of September 2001, which revealed the need for development and acquisition of medical countermeasures (vaccines, therapeutics, and diagnostics) to protect the U.S. population from chemical, biological, radiological, and nuclear (CBRN) threats.

PURPOSE



Accelerating Medical Countermeasure Development

1



Enhancing National Security

2

PRODUCTS

Three (3) therapeutics for treatment of inhalational anthrax (**Raxibacumab**®, **Anthrasil**®, and **Anthim**®);

BioThrax® vaccine and the next-generation **CYFENDUS**® vaccine for post-exposure prophylaxis of anthrax;

HBAT for treatment of symptomatic botulism;

JYNNEOS® vaccine for prevention of smallpox infection in people where replicating smallpox vaccines are contraindicated, and for mpox in healthy adults;

TPOXX® (oral and intravenous) and **TEMBEXA**® (capsule and suspension) for treatment of smallpox infection;

Seizalam® for treatment of status epilepticus (a common side effect of nerve agents);

OPVEE® intranasal nalmefene for opioid overdose;

Seven (7) countermeasures for treatment of the effects of radiation exposure (**Nplate**®, **Neupogen**®, **Leukine**®, **Neulasta**®, **Thyroshield**®, **Ca-DTPA** and **Zn-DTPA**)

Nexobrid®, **RECELL**® (two approvals), and **StrataGraft**® for treatment of injuries due to thermal burns;

Sliverlon®, an antimicrobial wound dressing for treatment of skin injuries due to chemical and thermal burns;

ERVEBO® vaccine for prevention of Ebola Zaire Disease;

NUZYRA® for treatment of anthrax and community-acquired bacterial pneumonia;

Inmazoleb® for treatment of Ebola Virus Disease;

Allograft skin for treatment of burn wounds.

RESULTS

39
MCMs funded
under Project BioShield

27
products
procured for national preparedness

12
products
maintained via vendor managed inventory

1. Investing in Health Security

By investing in research, development, and procurement upfront, Project BioShield helps ensure that the necessary tools and resources are available when needed. This proactive approach enhances the nation's preparedness for potential biological emergencies and reduces the time it takes to respond.

2. Continuous Success

The continuous success of the PBS Program, as instituted by the Project BioShield Act, demonstrates the U.S. government's commitment through public-private partnerships to supporting the development and procurement of medical countermeasures and long-term sustainability of the nation's biodefense capabilities.

